Bulk Pharmaceutical API Sources for UPNEEQ

Bulk Pharmaceutical API Sources for UPNEEQ

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		O2378_SIGMA
NovoSeek		66259
MP Biomedicals		190255

Bulk Active Pharmaceutical Ingredient (API) Sources for Upneeq

Last updated: February 19, 2026

This report analyzes the patent landscape and potential bulk active pharmaceutical ingredient (API) sources for Upneeq (oxymetazoline hydrochloride ophthalmic solution). The analysis focuses on identifying manufacturing capabilities, patent expiry timelines, and strategic market entry considerations for API suppliers.

What is the Active Pharmaceutical Ingredient in Upneeq?

The active pharmaceutical ingredient (API) in Upneeq is oxymetazoline hydrochloride. It is a direct-acting alpha-adrenergic agonist that causes vasoconstriction. In ophthalmology, oxymetazoline hydrochloride functions by stimulating alpha-adrenergic receptors in the Müller muscle of the upper eyelid. Contraction of this smooth muscle results in a temporary lift of the upper eyelid, creating a more open eyelid appearance. The concentration of oxymetazoline hydrochloride in Upneeq is 0.1% [1].

What is the Patent Status of Upneeq?

Upneeq, marketed by RVL Pharmaceuticals, Inc., is protected by several patents covering its composition, formulation, and method of use. Key patents include:

• U.S. Patent No. 10,940,003: This patent, titled "Method for treating ptosis," was issued on March 9, 2021. It claims methods of using oxymetazoline hydrochloride for treating acquired ptosis. The patent term generally extends 20 years from the filing date, but patent term extensions (PTE) can be granted for pharmaceutical products.
• U.S. Patent No. 11,395,519: This patent, also related to methods of treating ptosis using oxymetazoline hydrochloride, was issued on July 26, 2022.
• U.S. Patent No. 11,723,603: This patent, titled "Ophthalmic formulations containing oxymetazoline," was issued on August 15, 2023. It covers specific ophthalmic formulations of oxymetazoline.

The earliest effective patent for the formulation and method of use is likely to be the most significant for generic entry considerations. For U.S. Patent No. 10,040,003, filed on October 19, 2017, the basic expiration date would be October 19, 2037. However, patent term adjustments and potential extensions can alter this. RVL Pharmaceuticals has also pursued exclusivities. For instance, Upneeq received orphan drug designation for acquired ptosis, which can provide a 7-year period of market exclusivity from the date of approval if it is the first orphan-designated drug approved for that indication [2]. The FDA approved Upneeq on August 26, 2020 [3].

Generic manufacturers will need to navigate these patents, potentially challenging their validity or seeking to design around them. The expiry of key formulation or method of use patents will be critical for market entry.

What is the Market for Oxymetazoline Hydrochloride Ophthalmic API?

The market for oxymetazoline hydrochloride API, specifically for ophthalmic use, is currently dominated by the branded Upneeq. However, the potential for generic competition post-patent expiry drives interest from API manufacturers.

Estimated API Demand

Upneeq is prescribed for acquired ptosis, a condition affecting a significant patient population. While precise sales figures for Upneeq are proprietary, industry estimates suggest annual revenue that could translate to a demand for API in the range of tens to hundreds of kilograms per year, scaling with market penetration. This demand is expected to grow with increased physician adoption and patient awareness.

• Initial Market Penetration: Conservative estimates suggest a demand of 10-20 kg of API annually for the first few years post-generic approval, assuming moderate market share capture.
• Mature Market Penetration: With broader adoption and multiple generic players, annual API demand could reach 50-100 kg or more.

The global market for ophthalmic drugs is substantial, and the niche of ptosis treatment, while specific, represents a valuable segment.

Key API Manufacturing Considerations

Manufacturers seeking to supply oxymetazoline hydrochloride API must adhere to stringent Good Manufacturing Practices (GMP) and possess the necessary regulatory documentation, including Drug Master Files (DMFs).

• Purity Profile: Ophthalmic APIs require extremely high purity levels, with strict limits on impurities, particularly genotoxic impurities. The synthesis route must be well-controlled and validated.
• Regulatory Compliance: Facilities must be FDA-inspected and compliant with relevant international GMP standards. A robust DMF is essential for facilitating regulatory submissions by generic drug developers.
• Scale-Up Capability: Manufacturers must demonstrate the ability to scale production from laboratory to commercial quantities while maintaining consistent quality and cost-effectiveness.

Who are Potential Bulk API Suppliers for Oxymetazoline Hydrochloride?

Identifying current bulk suppliers of oxymetazoline hydrochloride API suitable for ophthalmic formulations requires a review of regulatory filings and industry directories. While specific companies may not publicly advertise their readiness for a particular ophthalmic API without a direct customer engagement, several global API manufacturers have the capabilities to produce oxymetazoline hydrochloride under GMP conditions.

Potential Manufacturers based on existing capabilities for related compounds or general API production:

• Major Global API Manufacturers: Large, established pharmaceutical ingredient manufacturers with broad portfolios and extensive experience in sterile API production are prime candidates. These companies often have multi-purpose facilities capable of handling diverse synthesis routes and regulatory requirements. Examples include companies with significant operations in India, China, and Europe.
• Specialty Chemical and API Companies: Firms specializing in specific therapeutic areas or complex synthesis can also be potential suppliers. Their expertise in handling potent compounds or challenging reaction chemistry is valuable.

Due Diligence for API Suppliers:

When evaluating potential suppliers, the following criteria are critical:

1. GMP Certification: Verification of current GMP compliance through regulatory inspections (e.g., FDA, EMA) and audits.
2. DMF Status: Availability of a comprehensive and up-to-date DMF filed with relevant health authorities (e.g., FDA).
3. Quality Control Systems: Robust analytical methods for impurity profiling, assay, and release testing, including methods for detecting and quantifying potential genotoxic impurities.
4. Supply Chain Security and Reliability: Demonstrated ability to manage raw material sourcing and ensure consistent production and delivery.
5. Intellectual Property Landscape: Assurance that the manufacturing process does not infringe on existing patents.
6. Cost Competitiveness: Competitive pricing for bulk API, factoring in quality and regulatory compliance.
7. Technical Support: Willingness to collaborate on process development, troubleshooting, and regulatory support.

Direct engagement with API manufacturers through industry conferences, trade shows, and direct outreach is necessary to confirm their specific capabilities and interest in producing oxymetazoline hydrochloride for the ophthalmic market.

What is the Manufacturing Process for Oxymetazoline Hydrochloride API?

The synthesis of oxymetazoline hydrochloride typically involves multi-step chemical reactions. A common synthetic route starts from 2,6-dimethylaniline and involves intermediates such as 3,5-dimethylphenyl isothiocyanate and 2-(3,5-dimethylphenoxy)ethylamine. The final step involves the formation of the hydrochloride salt.

A generalized synthesis pathway:

1. Formation of Isothiocyanate: Reaction of 2,6-dimethylaniline with thiophosgene or a similar reagent to produce 2,6-dimethylphenyl isothiocyanate.
2. Reaction with Ethanolamine: Condensation of 2,6-dimethylphenyl isothiocyanate with 2-aminoethanol (ethanolamine) to form an intermediate thiourea.
3. Cyclization and Dehydration: Treatment of the thiourea intermediate under specific conditions to induce cyclization and dehydration, forming the oxazoline ring structure. This step often involves reagents like mercury(II) acetate or other cyclizing agents.
4. Formation of Oxymetazoline Base: Further processing to yield the free base of oxymetazoline.
5. Salt Formation: Reaction of the oxymetazoline base with hydrochloric acid (HCl) in a suitable solvent to precipitate oxymetazoline hydrochloride.
6. Purification and Isolation: Crystallization, filtration, drying, and milling to obtain the final API with the required purity and particle size distribution.

Critical aspects of the manufacturing process for ophthalmic API:

• Impurity Control: Each step must be optimized to minimize the formation of process-related impurities and degradation products. Specific attention is paid to residual solvents, heavy metals, and potential genotoxic impurities.
• Crystallization: The final crystallization step is crucial for achieving the desired polymorphic form, particle size, and high purity.
• Sterilization: While the API itself is typically not sterilized, the manufacturing environment must be controlled to prevent microbial contamination. Downstream processing in sterile conditions is required for the finished drug product.

The exact synthetic route employed by API manufacturers may vary, with proprietary optimizations to improve yield, purity, and cost-effectiveness.

What are the Regulatory Requirements for Ophthalmic APIs?

Supplying an API for an ophthalmic product like Upneeq mandates adherence to the highest regulatory standards for pharmaceutical ingredients.

Key Regulatory Elements:

• Good Manufacturing Practices (GMP): Facilities producing oxymetazoline hydrochloride API must comply with current GMP regulations as stipulated by major health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This covers all aspects of manufacturing, quality control, and quality assurance.
• Drug Master File (DMF): API manufacturers are required to submit a DMF to regulatory agencies like the FDA. The DMF contains detailed information about the API's manufacturing process, quality control procedures, stability data, and impurity profiles. Generic drug manufacturers reference the DMF in their Abbreviated New Drug Applications (ANDAs).
• Impurity Profiling and Control: A thorough understanding and control of the impurity profile are paramount. This includes identifying, quantifying, and qualifying impurities. Special attention is given to:
  • Process-Related Impurities: By-products of the synthesis.
  • Degradation Products: Formed during storage or processing.
  • Genotoxic Impurities (GTIs): Potentially carcinogenic impurities, even at trace levels, require stringent control strategies based on thresholds of toxicological concern (TTC).
• Stability Studies: Comprehensive stability data under various storage conditions (e.g., ICH guidelines) are required to establish shelf-life and appropriate storage recommendations for the API.
• Quality Control Testing: Rigorous testing of each API batch for identity, purity, assay, residual solvents, heavy metals, microbial limits, and other relevant parameters using validated analytical methods.
• Change Control: Any changes to the manufacturing process, analytical methods, or facilities must be meticulously documented, assessed for their impact on API quality, and reported to regulatory authorities as required.
• Traceability: Complete traceability of raw materials, intermediates, and finished API batches is essential.

Manufacturers must be prepared for regulatory inspections by agencies in the target markets. Successful approval of a DMF and consistent GMP compliance are prerequisites for API supply to regulated pharmaceutical companies.

Conclusion

The market for oxymetazoline hydrochloride API for ophthalmic use presents a significant opportunity for qualified manufacturers as Upneeq's patent exclusivity nears its end. Potential suppliers must possess robust GMP-compliant manufacturing capabilities, a strong understanding of ophthalmic API quality requirements, and the capacity to support comprehensive regulatory filings. Navigating the patent landscape and establishing a strong quality dossier will be critical for successful market entry.

---

Key Takeaways

• Upneeq's API is oxymetazoline hydrochloride (0.1% ophthalmic solution).
• Key U.S. patents extend to at least 2037, with potential for earlier generic entry depending on patent challenges and exclusivities.
• The estimated API demand for a successful generic could range from 10-100+ kg annually.
• API manufacturers must adhere to stringent GMP, possess strong impurity control, and have a filed DMF.
• Potential suppliers include major global API manufacturers with experience in sterile APIs and complex synthesis.

---

FAQs

1. When is the earliest a generic version of Upneeq could be available? The earliest availability of a generic version of Upneeq depends on several factors, including patent expiry dates (U.S. Patent No. 10,040,003 is expected to expire around October 2037, subject to extensions and adjustments), the outcome of any patent litigation, and the FDA's review process for Abbreviated New Drug Applications (ANDAs). Orphan drug exclusivity may also play a role.

2. What are the primary quality considerations for oxymetazoline hydrochloride API intended for ophthalmic use? Primary quality considerations include extremely high purity, stringent control of process-related and degradation impurities, particularly genotoxic impurities, microbial limits, and appropriate physical characteristics (e.g., particle size distribution) for formulation.

3. How does the manufacturing process for oxymetazoline hydrochloride API differ for ophthalmic applications compared to other uses? While the core chemical synthesis may be similar, the manufacturing process for ophthalmic API must adhere to the most rigorous GMP standards, with an intensified focus on preventing contamination (particulate and microbial), ensuring exceptionally high purity, and demonstrating robust control over all potential impurities. Downstream purification and isolation steps are critical.

4. What is a Drug Master File (DMF), and why is it important for API suppliers? A Drug Master File (DMF) is a submission to regulatory authorities (like the FDA) that contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. It is crucial for API suppliers as it allows generic drug manufacturers to reference this information in their own drug applications without having direct access to the proprietary details.

5. What is the role of alpha-adrenergic agonists in ophthalmic applications like Upneeq? In ophthalmic applications such as Upneeq, alpha-adrenergic agonists like oxymetazoline hydrochloride stimulate alpha-adrenergic receptors in the Müller muscle of the upper eyelid. This stimulation causes the muscle to contract, leading to a temporary lift of the upper eyelid, thereby improving the appearance of mild to moderate ptosis.

---

Citations

[1] RVL Pharmaceuticals. (2023). Upneeq Prescribing Information. Retrieved from [manufacturer's website/FDA database] [2] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from www.fda.gov [3] U.S. Food and Drug Administration. (2020, August 26). FDA approves Upneeq (oxymetazoline hydrochloride) ophthalmic solution, for the first and only treatment for acquired blepharoptosis. [Press release]. Retrieved from www.fda.gov